Tasly Holding Group

 Tasly, through innovations in standards and technologies, has created a manufacturing process for TCM modernization and set up an internationalized advanced, standardized, digital and intelligent big industrial system which produces high-quality, stable and controllable TCM products. Utilizing ground-breaking technology and cutting-edge science, Tasly has performed over 1000 clinical research trials and it has developed chemical-free medications which have been approved by FDA, the medicine have been lauched in 34 countries benefiting over a billion patients worldwide. 

 Tasly's Danshen Compound Dripping Pill (Dantonic) is the first Chinese herbal compound medicine that got FDA IND clinical application. In 2007, Tasly launched FDA phaseII clinical trials which was carried out in 15 American clinical centers including New York, Florida, Texas and California, etc. All the clinical trials strictly followed international recognized standard—GCP Clinical Trial Standards. The trail was completed in Aug.2010 and it marked that Dantonic became the first Chinese patent medicine approved by FDA phaseII clinical trials and confirmed as a safe and efficient Chinese herbal compound. Dantonic is currently undergoing FDA phase III clinical trials in 137 sites throughout North America and Europe. It is expected to be the first and only natural, chemical-free, compounded TCM approved by the FDA. 

 Meanwhile, on the basis of technological advantage in bio-medical area, Tasly has expanded its business to health industry and initiated the concept of Pan-health. Tasly has been making effort for years in order to become innovator of Pan-health products, designer of Pan-health management plan and practitioner of Pan-health culture. Therefore, Tasly has been concentrating on its ‘Six One Project’: a box of medicine, a bottle water, a cup tea, a glass of liquor, a health management plan,and a platform for children's education, in order to achieve the goal of “optimized birth, prolonged life, delayed diseases, and pacified leave”. 

Tasly Pharmaceutical International, the performer of Tasly’s ( Tasly Holding Group ) international marketing strategy which is running independently, after more than ten years efforts, has opened overseas branches and representative offices in 21 nations or regions and 4 chain TCM clinics in 4 countries, which constitute a marketing network covering 40-odd countries and tens of thousands of distributors of different nationalities. The firm has registered more than 50 products in over 40 countries as adjuvant, health product and functional food.

Setting “complete globalization” as its strategic development target, Tasly has expanded its marketing network worldwide which is composed of the African market around Nigeria, the ASEAN market around Vietnam, the Asian market around Japan, the EU market around the Netherlands, the Oceanian market around Australia and the North American market around the U.S. By 2013 the firm has exported products subject to more than 10 categories of inspections and examinations to 35 ports and airports of 23 countries in 4 continents, America, Europe, Africa and Asia.

 In 2010 Tasly Pharmaceutical International was honored by CCCMHPIE (Chinese Chamber of Commerce for Import & Export of Medicines and Health Products) subordinate to the Ministry of Commerce with “China Top 5 CPM Exporters”, shooting to fame among the over 2,600 peers engaging in TCM export; in September 2011 Tasly was voted “Top 50 Globalized Chinese Enterprises of 2011” in the rankings of Chinese enterprises by globalization released during the Bridges China Dialogue in Geneva, Switzerland; in 2012 Tasly won the “China Top 5 CPM Exporters” from CCCMHPIE and the “2011-2012 Top 10 Promoters of TCM Globalization”.